nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—ABCB1—Mitomycin—urinary bladder cancer	0.0949	0.292	CbGbCtD
Sirolimus—SLCO1B1—Methotrexate—urinary bladder cancer	0.045	0.138	CbGbCtD
Sirolimus—CYP3A4—Thiotepa—urinary bladder cancer	0.0431	0.132	CbGbCtD
Sirolimus—CYP3A5—Etoposide—urinary bladder cancer	0.03	0.0921	CbGbCtD
Sirolimus—ABCB1—Gemcitabine—urinary bladder cancer	0.0273	0.0839	CbGbCtD
Sirolimus—ABCB1—Cisplatin—urinary bladder cancer	0.0198	0.061	CbGbCtD
Sirolimus—ABCB1—Etoposide—urinary bladder cancer	0.0195	0.0599	CbGbCtD
Sirolimus—ABCB1—Doxorubicin—urinary bladder cancer	0.0133	0.0409	CbGbCtD
Sirolimus—ABCB1—Methotrexate—urinary bladder cancer	0.0129	0.0396	CbGbCtD
Sirolimus—CYP3A4—Etoposide—urinary bladder cancer	0.0117	0.0359	CbGbCtD
Sirolimus—EIF4E—prostate gland—urinary bladder cancer	0.0104	0.0888	CbGeAlD
Sirolimus—CYP3A4—Doxorubicin—urinary bladder cancer	0.00797	0.0245	CbGbCtD
Sirolimus—EIF4E—renal system—urinary bladder cancer	0.00712	0.0605	CbGeAlD
Sirolimus—FGF2—prostate gland—urinary bladder cancer	0.00637	0.0542	CbGeAlD
Sirolimus—EIF4E—female reproductive system—urinary bladder cancer	0.0057	0.0485	CbGeAlD
Sirolimus—FGF2—smooth muscle tissue—urinary bladder cancer	0.00451	0.0383	CbGeAlD
Sirolimus—FGF2—urethra—urinary bladder cancer	0.00427	0.0363	CbGeAlD
Sirolimus—MTOR—prostate gland—urinary bladder cancer	0.00404	0.0344	CbGeAlD
Sirolimus—FKBP1A—prostate gland—urinary bladder cancer	0.00364	0.0309	CbGeAlD
Sirolimus—MTOR—seminal vesicle—urinary bladder cancer	0.00342	0.0291	CbGeAlD
Sirolimus—CYP3A4—urine—urinary bladder cancer	0.00331	0.0281	CbGeAlD
Sirolimus—FGF2—vagina—urinary bladder cancer	0.00314	0.0267	CbGeAlD
Sirolimus—SLC47A1—prostate gland—urinary bladder cancer	0.00312	0.0266	CbGeAlD
Sirolimus—FKBP1A—seminal vesicle—urinary bladder cancer	0.00307	0.0261	CbGeAlD
Sirolimus—MTOR—epithelium—urinary bladder cancer	0.00297	0.0252	CbGeAlD
Sirolimus—MTOR—smooth muscle tissue—urinary bladder cancer	0.00286	0.0243	CbGeAlD
Sirolimus—MTOR—renal system—urinary bladder cancer	0.00275	0.0234	CbGeAlD
Sirolimus—FKBP1A—epithelium—urinary bladder cancer	0.00267	0.0227	CbGeAlD
Sirolimus—SLC47A1—seminal vesicle—urinary bladder cancer	0.00264	0.0225	CbGeAlD
Sirolimus—FKBP1A—smooth muscle tissue—urinary bladder cancer	0.00257	0.0219	CbGeAlD
Sirolimus—FKBP1A—renal system—urinary bladder cancer	0.00248	0.0211	CbGeAlD
Sirolimus—FKBP1A—urethra—urinary bladder cancer	0.00243	0.0207	CbGeAlD
Sirolimus—MTOR—female reproductive system—urinary bladder cancer	0.00221	0.0188	CbGeAlD
Sirolimus—SLC47A1—renal system—urinary bladder cancer	0.00213	0.0181	CbGeAlD
Sirolimus—SLCO1B1—renal system—urinary bladder cancer	0.0021	0.0179	CbGeAlD
Sirolimus—SLC47A1—urethra—urinary bladder cancer	0.00209	0.0178	CbGeAlD
Sirolimus—FGF2—lymph node—urinary bladder cancer	0.00203	0.0173	CbGeAlD
Sirolimus—MTOR—vagina—urinary bladder cancer	0.002	0.017	CbGeAlD
Sirolimus—FKBP1A—female reproductive system—urinary bladder cancer	0.00198	0.0169	CbGeAlD
Sirolimus—FKBP1A—vagina—urinary bladder cancer	0.00179	0.0153	CbGeAlD
Sirolimus—SLC47A1—female reproductive system—urinary bladder cancer	0.00171	0.0145	CbGeAlD
Sirolimus—SLCO1B1—female reproductive system—urinary bladder cancer	0.00168	0.0143	CbGeAlD
Sirolimus—CYP3A5—prostate gland—urinary bladder cancer	0.00158	0.0135	CbGeAlD
Sirolimus—SLC47A1—vagina—urinary bladder cancer	0.00154	0.0131	CbGeAlD
Sirolimus—MTOR—lymph node—urinary bladder cancer	0.00129	0.011	CbGeAlD
Sirolimus—FKBP1A—lymph node—urinary bladder cancer	0.00116	0.00987	CbGeAlD
Sirolimus—CYP3A5—renal system—urinary bladder cancer	0.00108	0.00917	CbGeAlD
Sirolimus—SLC47A1—lymph node—urinary bladder cancer	0.000998	0.00848	CbGeAlD
Sirolimus—ABCB1—prostate gland—urinary bladder cancer	0.000841	0.00715	CbGeAlD
Sirolimus—CYP3A4—renal system—urinary bladder cancer	0.00081	0.00688	CbGeAlD
Sirolimus—CYP3A5—vagina—urinary bladder cancer	0.000782	0.00664	CbGeAlD
Sirolimus—ABCB1—seminal vesicle—urinary bladder cancer	0.000711	0.00605	CbGeAlD
Sirolimus—CYP3A4—female reproductive system—urinary bladder cancer	0.000648	0.00551	CbGeAlD
Sirolimus—ABCB1—epithelium—urinary bladder cancer	0.000618	0.00525	CbGeAlD
Sirolimus—ABCB1—renal system—urinary bladder cancer	0.000573	0.00487	CbGeAlD
Sirolimus—ABCB1—urethra—urinary bladder cancer	0.000563	0.00479	CbGeAlD
Sirolimus—ABCB1—female reproductive system—urinary bladder cancer	0.000459	0.0039	CbGeAlD
Sirolimus—ABCB1—vagina—urinary bladder cancer	0.000415	0.00353	CbGeAlD
Sirolimus—ABCB1—lymph node—urinary bladder cancer	0.000269	0.00228	CbGeAlD
Sirolimus—Urethral disorder—Methotrexate—urinary bladder cancer	0.000126	0.00037	CcSEcCtD
Sirolimus—Weight decreased—Doxorubicin—urinary bladder cancer	0.000126	0.00037	CcSEcCtD
Sirolimus—Sinusitis—Epirubicin—urinary bladder cancer	0.000126	0.000369	CcSEcCtD
Sirolimus—Feeling abnormal—Etoposide—urinary bladder cancer	0.000126	0.000369	CcSEcCtD
Sirolimus—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000125	0.000368	CcSEcCtD
Sirolimus—Pneumonia—Doxorubicin—urinary bladder cancer	0.000125	0.000366	CcSEcCtD
Sirolimus—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000125	0.000366	CcSEcCtD
Sirolimus—Pruritus—Fluorouracil—urinary bladder cancer	0.000124	0.000365	CcSEcCtD
Sirolimus—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000124	0.000364	CcSEcCtD
Sirolimus—Infestation—Doxorubicin—urinary bladder cancer	0.000124	0.000364	CcSEcCtD
Sirolimus—Visual impairment—Methotrexate—urinary bladder cancer	0.000124	0.000364	CcSEcCtD
Sirolimus—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000123	0.00036	CcSEcCtD
Sirolimus—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000122	0.000359	CcSEcCtD
Sirolimus—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000122	0.000357	CcSEcCtD
Sirolimus—Haemoglobin—Epirubicin—urinary bladder cancer	0.000121	0.000355	CcSEcCtD
Sirolimus—Stomatitis—Doxorubicin—urinary bladder cancer	0.000121	0.000355	CcSEcCtD
Sirolimus—Rhinitis—Epirubicin—urinary bladder cancer	0.000121	0.000354	CcSEcCtD
Sirolimus—Body temperature increased—Etoposide—urinary bladder cancer	0.000121	0.000354	CcSEcCtD
Sirolimus—Abdominal pain—Etoposide—urinary bladder cancer	0.000121	0.000354	CcSEcCtD
Sirolimus—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000121	0.000354	CcSEcCtD
Sirolimus—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000121	0.000354	CcSEcCtD
Sirolimus—Haemorrhage—Epirubicin—urinary bladder cancer	0.00012	0.000353	CcSEcCtD
Sirolimus—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00012	0.000353	CcSEcCtD
Sirolimus—Tinnitus—Methotrexate—urinary bladder cancer	0.00012	0.000352	CcSEcCtD
Sirolimus—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.00012	0.000352	CcSEcCtD
Sirolimus—Asthenia—Cisplatin—urinary bladder cancer	0.000119	0.000351	CcSEcCtD
Sirolimus—Pharyngitis—Epirubicin—urinary bladder cancer	0.000119	0.000351	CcSEcCtD
Sirolimus—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000119	0.00035	CcSEcCtD
Sirolimus—Sweating—Doxorubicin—urinary bladder cancer	0.000119	0.000349	CcSEcCtD
Sirolimus—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000119	0.000349	CcSEcCtD
Sirolimus—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000119	0.000348	CcSEcCtD
Sirolimus—Haematuria—Doxorubicin—urinary bladder cancer	0.000118	0.000347	CcSEcCtD
Sirolimus—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000118	0.000347	CcSEcCtD
Sirolimus—Urethral disorder—Epirubicin—urinary bladder cancer	0.000118	0.000346	CcSEcCtD
Sirolimus—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000117	0.000344	CcSEcCtD
Sirolimus—Epistaxis—Doxorubicin—urinary bladder cancer	0.000117	0.000344	CcSEcCtD
Sirolimus—Angiopathy—Methotrexate—urinary bladder cancer	0.000117	0.000343	CcSEcCtD
Sirolimus—Sinusitis—Doxorubicin—urinary bladder cancer	0.000116	0.000342	CcSEcCtD
Sirolimus—Immune system disorder—Methotrexate—urinary bladder cancer	0.000116	0.000341	CcSEcCtD
Sirolimus—Dizziness—Fluorouracil—urinary bladder cancer	0.000116	0.000341	CcSEcCtD
Sirolimus—Visual impairment—Epirubicin—urinary bladder cancer	0.000116	0.000341	CcSEcCtD
Sirolimus—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000116	0.00034	CcSEcCtD
Sirolimus—Chills—Methotrexate—urinary bladder cancer	0.000115	0.000339	CcSEcCtD
Sirolimus—Diarrhoea—Cisplatin—urinary bladder cancer	0.000114	0.000335	CcSEcCtD
Sirolimus—Vomiting—Gemcitabine—urinary bladder cancer	0.000114	0.000333	CcSEcCtD
Sirolimus—Rash—Gemcitabine—urinary bladder cancer	0.000113	0.000331	CcSEcCtD
Sirolimus—Dermatitis—Gemcitabine—urinary bladder cancer	0.000112	0.00033	CcSEcCtD
Sirolimus—Hypersensitivity—Etoposide—urinary bladder cancer	0.000112	0.00033	CcSEcCtD
Sirolimus—Tinnitus—Epirubicin—urinary bladder cancer	0.000112	0.000329	CcSEcCtD
Sirolimus—Malnutrition—Methotrexate—urinary bladder cancer	0.000112	0.000329	CcSEcCtD
Sirolimus—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000112	0.000329	CcSEcCtD
Sirolimus—Headache—Gemcitabine—urinary bladder cancer	0.000112	0.000329	CcSEcCtD
Sirolimus—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000112	0.000328	CcSEcCtD
Sirolimus—Vomiting—Fluorouracil—urinary bladder cancer	0.000112	0.000328	CcSEcCtD
Sirolimus—Rhinitis—Doxorubicin—urinary bladder cancer	0.000112	0.000328	CcSEcCtD
Sirolimus—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000111	0.000327	CcSEcCtD
Sirolimus—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000111	0.000325	CcSEcCtD
Sirolimus—Rash—Fluorouracil—urinary bladder cancer	0.000111	0.000325	CcSEcCtD
Sirolimus—Dermatitis—Fluorouracil—urinary bladder cancer	0.000111	0.000325	CcSEcCtD
Sirolimus—Pharyngitis—Doxorubicin—urinary bladder cancer	0.00011	0.000325	CcSEcCtD
Sirolimus—Headache—Fluorouracil—urinary bladder cancer	0.00011	0.000323	CcSEcCtD
Sirolimus—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.00011	0.000323	CcSEcCtD
Sirolimus—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.00011	0.000322	CcSEcCtD
Sirolimus—Asthenia—Etoposide—urinary bladder cancer	0.000109	0.000321	CcSEcCtD
Sirolimus—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000109	0.000321	CcSEcCtD
Sirolimus—Angiopathy—Epirubicin—urinary bladder cancer	0.000109	0.000321	CcSEcCtD
Sirolimus—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000109	0.000321	CcSEcCtD
Sirolimus—Immune system disorder—Epirubicin—urinary bladder cancer	0.000109	0.000319	CcSEcCtD
Sirolimus—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000108	0.000318	CcSEcCtD
Sirolimus—Back pain—Methotrexate—urinary bladder cancer	0.000108	0.000318	CcSEcCtD
Sirolimus—Chills—Epirubicin—urinary bladder cancer	0.000108	0.000317	CcSEcCtD
Sirolimus—Pruritus—Etoposide—urinary bladder cancer	0.000108	0.000317	CcSEcCtD
Sirolimus—Visual impairment—Doxorubicin—urinary bladder cancer	0.000107	0.000315	CcSEcCtD
Sirolimus—Nausea—Gemcitabine—urinary bladder cancer	0.000106	0.000312	CcSEcCtD
Sirolimus—Vomiting—Cisplatin—urinary bladder cancer	0.000106	0.000311	CcSEcCtD
Sirolimus—Rash—Cisplatin—urinary bladder cancer	0.000105	0.000308	CcSEcCtD
Sirolimus—Dermatitis—Cisplatin—urinary bladder cancer	0.000105	0.000308	CcSEcCtD
Sirolimus—Malnutrition—Epirubicin—urinary bladder cancer	0.000105	0.000308	CcSEcCtD
Sirolimus—Diarrhoea—Etoposide—urinary bladder cancer	0.000104	0.000306	CcSEcCtD
Sirolimus—Nausea—Fluorouracil—urinary bladder cancer	0.000104	0.000306	CcSEcCtD
Sirolimus—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000104	0.000305	CcSEcCtD
Sirolimus—Tinnitus—Doxorubicin—urinary bladder cancer	0.000104	0.000305	CcSEcCtD
Sirolimus—Anaemia—Methotrexate—urinary bladder cancer	0.000103	0.000304	CcSEcCtD
Sirolimus—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000103	0.000303	CcSEcCtD
Sirolimus—Flatulence—Epirubicin—urinary bladder cancer	0.000103	0.000303	CcSEcCtD
Sirolimus—Tension—Epirubicin—urinary bladder cancer	0.000103	0.000302	CcSEcCtD
Sirolimus—Nervousness—Epirubicin—urinary bladder cancer	0.000102	0.000299	CcSEcCtD
Sirolimus—Back pain—Epirubicin—urinary bladder cancer	0.000101	0.000298	CcSEcCtD
Sirolimus—Angiopathy—Doxorubicin—urinary bladder cancer	0.000101	0.000297	CcSEcCtD
Sirolimus—Malaise—Methotrexate—urinary bladder cancer	0.000101	0.000296	CcSEcCtD
Sirolimus—Dizziness—Etoposide—urinary bladder cancer	0.000101	0.000296	CcSEcCtD
Sirolimus—Muscle spasms—Epirubicin—urinary bladder cancer	0.000101	0.000296	CcSEcCtD
Sirolimus—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000101	0.000295	CcSEcCtD
Sirolimus—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.0001	0.000295	CcSEcCtD
Sirolimus—Leukopenia—Methotrexate—urinary bladder cancer	0.0001	0.000294	CcSEcCtD
Sirolimus—Chills—Doxorubicin—urinary bladder cancer	9.99e-05	0.000293	CcSEcCtD
Sirolimus—Nausea—Cisplatin—urinary bladder cancer	9.89e-05	0.00029	CcSEcCtD
Sirolimus—Cough—Methotrexate—urinary bladder cancer	9.77e-05	0.000287	CcSEcCtD
Sirolimus—Ill-defined disorder—Epirubicin—urinary bladder cancer	9.72e-05	0.000285	CcSEcCtD
Sirolimus—Vomiting—Etoposide—urinary bladder cancer	9.69e-05	0.000285	CcSEcCtD
Sirolimus—Malnutrition—Doxorubicin—urinary bladder cancer	9.69e-05	0.000285	CcSEcCtD
Sirolimus—Anaemia—Epirubicin—urinary bladder cancer	9.68e-05	0.000284	CcSEcCtD
Sirolimus—Agitation—Epirubicin—urinary bladder cancer	9.62e-05	0.000283	CcSEcCtD
Sirolimus—Rash—Etoposide—urinary bladder cancer	9.61e-05	0.000282	CcSEcCtD
Sirolimus—Dermatitis—Etoposide—urinary bladder cancer	9.61e-05	0.000282	CcSEcCtD
Sirolimus—Headache—Etoposide—urinary bladder cancer	9.55e-05	0.000281	CcSEcCtD
Sirolimus—Flatulence—Doxorubicin—urinary bladder cancer	9.55e-05	0.00028	CcSEcCtD
Sirolimus—Myalgia—Methotrexate—urinary bladder cancer	9.53e-05	0.00028	CcSEcCtD
Sirolimus—Chest pain—Methotrexate—urinary bladder cancer	9.53e-05	0.00028	CcSEcCtD
Sirolimus—Arthralgia—Methotrexate—urinary bladder cancer	9.53e-05	0.00028	CcSEcCtD
Sirolimus—Tension—Doxorubicin—urinary bladder cancer	9.51e-05	0.000279	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	9.46e-05	0.000278	CcSEcCtD
Sirolimus—Malaise—Epirubicin—urinary bladder cancer	9.44e-05	0.000277	CcSEcCtD
Sirolimus—Discomfort—Methotrexate—urinary bladder cancer	9.41e-05	0.000277	CcSEcCtD
Sirolimus—Nervousness—Doxorubicin—urinary bladder cancer	9.41e-05	0.000276	CcSEcCtD
Sirolimus—Syncope—Epirubicin—urinary bladder cancer	9.39e-05	0.000276	CcSEcCtD
Sirolimus—Leukopenia—Epirubicin—urinary bladder cancer	9.37e-05	0.000275	CcSEcCtD
Sirolimus—Back pain—Doxorubicin—urinary bladder cancer	9.37e-05	0.000275	CcSEcCtD
Sirolimus—Muscle spasms—Doxorubicin—urinary bladder cancer	9.32e-05	0.000274	CcSEcCtD
Sirolimus—Palpitations—Epirubicin—urinary bladder cancer	9.26e-05	0.000272	CcSEcCtD
Sirolimus—Confusional state—Methotrexate—urinary bladder cancer	9.21e-05	0.000271	CcSEcCtD
Sirolimus—Loss of consciousness—Epirubicin—urinary bladder cancer	9.2e-05	0.00027	CcSEcCtD
Sirolimus—Cough—Epirubicin—urinary bladder cancer	9.14e-05	0.000268	CcSEcCtD
Sirolimus—Anaphylactic shock—Methotrexate—urinary bladder cancer	9.13e-05	0.000268	CcSEcCtD
Sirolimus—Infection—Methotrexate—urinary bladder cancer	9.07e-05	0.000267	CcSEcCtD
Sirolimus—Nausea—Etoposide—urinary bladder cancer	9.06e-05	0.000266	CcSEcCtD
Sirolimus—Hypertension—Epirubicin—urinary bladder cancer	9.04e-05	0.000266	CcSEcCtD
Sirolimus—Ill-defined disorder—Doxorubicin—urinary bladder cancer	8.99e-05	0.000264	CcSEcCtD
Sirolimus—Nervous system disorder—Methotrexate—urinary bladder cancer	8.96e-05	0.000263	CcSEcCtD
Sirolimus—Anaemia—Doxorubicin—urinary bladder cancer	8.96e-05	0.000263	CcSEcCtD
Sirolimus—Thrombocytopenia—Methotrexate—urinary bladder cancer	8.94e-05	0.000263	CcSEcCtD
Sirolimus—Arthralgia—Epirubicin—urinary bladder cancer	8.92e-05	0.000262	CcSEcCtD
Sirolimus—Myalgia—Epirubicin—urinary bladder cancer	8.92e-05	0.000262	CcSEcCtD
Sirolimus—Chest pain—Epirubicin—urinary bladder cancer	8.92e-05	0.000262	CcSEcCtD
Sirolimus—Agitation—Doxorubicin—urinary bladder cancer	8.91e-05	0.000262	CcSEcCtD
Sirolimus—Anxiety—Epirubicin—urinary bladder cancer	8.89e-05	0.000261	CcSEcCtD
Sirolimus—Skin disorder—Methotrexate—urinary bladder cancer	8.87e-05	0.000261	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	8.85e-05	0.00026	CcSEcCtD
Sirolimus—Hyperhidrosis—Methotrexate—urinary bladder cancer	8.83e-05	0.000259	CcSEcCtD
Sirolimus—Discomfort—Epirubicin—urinary bladder cancer	8.81e-05	0.000259	CcSEcCtD
Sirolimus—Malaise—Doxorubicin—urinary bladder cancer	8.74e-05	0.000257	CcSEcCtD
Sirolimus—Anorexia—Methotrexate—urinary bladder cancer	8.71e-05	0.000256	CcSEcCtD
Sirolimus—Syncope—Doxorubicin—urinary bladder cancer	8.69e-05	0.000255	CcSEcCtD
Sirolimus—Leukopenia—Doxorubicin—urinary bladder cancer	8.67e-05	0.000255	CcSEcCtD
Sirolimus—Confusional state—Epirubicin—urinary bladder cancer	8.62e-05	0.000253	CcSEcCtD
Sirolimus—Palpitations—Doxorubicin—urinary bladder cancer	8.56e-05	0.000252	CcSEcCtD
Sirolimus—Anaphylactic shock—Epirubicin—urinary bladder cancer	8.55e-05	0.000251	CcSEcCtD
Sirolimus—Oedema—Epirubicin—urinary bladder cancer	8.55e-05	0.000251	CcSEcCtD
Sirolimus—Hypotension—Methotrexate—urinary bladder cancer	8.53e-05	0.000251	CcSEcCtD
Sirolimus—Loss of consciousness—Doxorubicin—urinary bladder cancer	8.52e-05	0.00025	CcSEcCtD
Sirolimus—Infection—Epirubicin—urinary bladder cancer	8.49e-05	0.000249	CcSEcCtD
Sirolimus—Cough—Doxorubicin—urinary bladder cancer	8.46e-05	0.000248	CcSEcCtD
Sirolimus—Shock—Epirubicin—urinary bladder cancer	8.41e-05	0.000247	CcSEcCtD
Sirolimus—Nervous system disorder—Epirubicin—urinary bladder cancer	8.38e-05	0.000246	CcSEcCtD
Sirolimus—Thrombocytopenia—Epirubicin—urinary bladder cancer	8.37e-05	0.000246	CcSEcCtD
Sirolimus—Hypertension—Doxorubicin—urinary bladder cancer	8.37e-05	0.000246	CcSEcCtD
Sirolimus—Tachycardia—Epirubicin—urinary bladder cancer	8.34e-05	0.000245	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	8.32e-05	0.000244	CcSEcCtD
Sirolimus—Skin disorder—Epirubicin—urinary bladder cancer	8.3e-05	0.000244	CcSEcCtD
Sirolimus—Hyperhidrosis—Epirubicin—urinary bladder cancer	8.26e-05	0.000243	CcSEcCtD
Sirolimus—Insomnia—Methotrexate—urinary bladder cancer	8.26e-05	0.000243	CcSEcCtD
Sirolimus—Arthralgia—Doxorubicin—urinary bladder cancer	8.25e-05	0.000242	CcSEcCtD
Sirolimus—Chest pain—Doxorubicin—urinary bladder cancer	8.25e-05	0.000242	CcSEcCtD
Sirolimus—Myalgia—Doxorubicin—urinary bladder cancer	8.25e-05	0.000242	CcSEcCtD
Sirolimus—Anxiety—Doxorubicin—urinary bladder cancer	8.22e-05	0.000241	CcSEcCtD
Sirolimus—Paraesthesia—Methotrexate—urinary bladder cancer	8.2e-05	0.000241	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	8.19e-05	0.000241	CcSEcCtD
Sirolimus—Discomfort—Doxorubicin—urinary bladder cancer	8.15e-05	0.000239	CcSEcCtD
Sirolimus—Anorexia—Epirubicin—urinary bladder cancer	8.15e-05	0.000239	CcSEcCtD
Sirolimus—Dyspnoea—Methotrexate—urinary bladder cancer	8.14e-05	0.000239	CcSEcCtD
Sirolimus—Somnolence—Methotrexate—urinary bladder cancer	8.12e-05	0.000238	CcSEcCtD
Sirolimus—Dyspepsia—Methotrexate—urinary bladder cancer	8.04e-05	0.000236	CcSEcCtD
Sirolimus—Hypotension—Epirubicin—urinary bladder cancer	7.99e-05	0.000235	CcSEcCtD
Sirolimus—Confusional state—Doxorubicin—urinary bladder cancer	7.97e-05	0.000234	CcSEcCtD
Sirolimus—Decreased appetite—Methotrexate—urinary bladder cancer	7.94e-05	0.000233	CcSEcCtD
Sirolimus—Oedema—Doxorubicin—urinary bladder cancer	7.91e-05	0.000232	CcSEcCtD
Sirolimus—Anaphylactic shock—Doxorubicin—urinary bladder cancer	7.91e-05	0.000232	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	7.89e-05	0.000232	CcSEcCtD
Sirolimus—Infection—Doxorubicin—urinary bladder cancer	7.86e-05	0.000231	CcSEcCtD
Sirolimus—Pain—Methotrexate—urinary bladder cancer	7.81e-05	0.000229	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	7.79e-05	0.000229	CcSEcCtD
Sirolimus—Shock—Doxorubicin—urinary bladder cancer	7.78e-05	0.000229	CcSEcCtD
Sirolimus—Nervous system disorder—Doxorubicin—urinary bladder cancer	7.76e-05	0.000228	CcSEcCtD
Sirolimus—Thrombocytopenia—Doxorubicin—urinary bladder cancer	7.74e-05	0.000227	CcSEcCtD
Sirolimus—Insomnia—Epirubicin—urinary bladder cancer	7.73e-05	0.000227	CcSEcCtD
Sirolimus—Tachycardia—Doxorubicin—urinary bladder cancer	7.72e-05	0.000227	CcSEcCtD
Sirolimus—Skin disorder—Doxorubicin—urinary bladder cancer	7.68e-05	0.000226	CcSEcCtD
Sirolimus—Paraesthesia—Epirubicin—urinary bladder cancer	7.68e-05	0.000225	CcSEcCtD
Sirolimus—Hyperhidrosis—Doxorubicin—urinary bladder cancer	7.65e-05	0.000225	CcSEcCtD
Sirolimus—Dyspnoea—Epirubicin—urinary bladder cancer	7.62e-05	0.000224	CcSEcCtD
Sirolimus—Somnolence—Epirubicin—urinary bladder cancer	7.6e-05	0.000223	CcSEcCtD
Sirolimus—Anorexia—Doxorubicin—urinary bladder cancer	7.54e-05	0.000221	CcSEcCtD
Sirolimus—Feeling abnormal—Methotrexate—urinary bladder cancer	7.53e-05	0.000221	CcSEcCtD
Sirolimus—Dyspepsia—Epirubicin—urinary bladder cancer	7.52e-05	0.000221	CcSEcCtD
Sirolimus—Gastrointestinal pain—Methotrexate—urinary bladder cancer	7.47e-05	0.000219	CcSEcCtD
Sirolimus—Decreased appetite—Epirubicin—urinary bladder cancer	7.43e-05	0.000218	CcSEcCtD
Sirolimus—Hypotension—Doxorubicin—urinary bladder cancer	7.39e-05	0.000217	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	7.38e-05	0.000217	CcSEcCtD
Sirolimus—Pain—Epirubicin—urinary bladder cancer	7.31e-05	0.000215	CcSEcCtD
Sirolimus—Constipation—Epirubicin—urinary bladder cancer	7.31e-05	0.000215	CcSEcCtD
Sirolimus—Body temperature increased—Methotrexate—urinary bladder cancer	7.22e-05	0.000212	CcSEcCtD
Sirolimus—Abdominal pain—Methotrexate—urinary bladder cancer	7.22e-05	0.000212	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	7.21e-05	0.000212	CcSEcCtD
Sirolimus—Insomnia—Doxorubicin—urinary bladder cancer	7.15e-05	0.00021	CcSEcCtD
Sirolimus—Paraesthesia—Doxorubicin—urinary bladder cancer	7.1e-05	0.000209	CcSEcCtD
Sirolimus—Dyspnoea—Doxorubicin—urinary bladder cancer	7.05e-05	0.000207	CcSEcCtD
Sirolimus—Feeling abnormal—Epirubicin—urinary bladder cancer	7.04e-05	0.000207	CcSEcCtD
Sirolimus—Somnolence—Doxorubicin—urinary bladder cancer	7.03e-05	0.000207	CcSEcCtD
Sirolimus—Gastrointestinal pain—Epirubicin—urinary bladder cancer	6.99e-05	0.000205	CcSEcCtD
Sirolimus—Dyspepsia—Doxorubicin—urinary bladder cancer	6.96e-05	0.000204	CcSEcCtD
Sirolimus—Decreased appetite—Doxorubicin—urinary bladder cancer	6.87e-05	0.000202	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	6.83e-05	0.000201	CcSEcCtD
Sirolimus—Constipation—Doxorubicin—urinary bladder cancer	6.76e-05	0.000199	CcSEcCtD
Sirolimus—Pain—Doxorubicin—urinary bladder cancer	6.76e-05	0.000199	CcSEcCtD
Sirolimus—Abdominal pain—Epirubicin—urinary bladder cancer	6.76e-05	0.000198	CcSEcCtD
Sirolimus—Body temperature increased—Epirubicin—urinary bladder cancer	6.76e-05	0.000198	CcSEcCtD
Sirolimus—Hypersensitivity—Methotrexate—urinary bladder cancer	6.73e-05	0.000198	CcSEcCtD
Sirolimus—Asthenia—Methotrexate—urinary bladder cancer	6.55e-05	0.000192	CcSEcCtD
Sirolimus—Feeling abnormal—Doxorubicin—urinary bladder cancer	6.52e-05	0.000191	CcSEcCtD
Sirolimus—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	6.47e-05	0.00019	CcSEcCtD
Sirolimus—Pruritus—Methotrexate—urinary bladder cancer	6.46e-05	0.00019	CcSEcCtD
Sirolimus—Hypersensitivity—Epirubicin—urinary bladder cancer	6.3e-05	0.000185	CcSEcCtD
Sirolimus—Abdominal pain—Doxorubicin—urinary bladder cancer	6.25e-05	0.000184	CcSEcCtD
Sirolimus—Body temperature increased—Doxorubicin—urinary bladder cancer	6.25e-05	0.000184	CcSEcCtD
Sirolimus—Diarrhoea—Methotrexate—urinary bladder cancer	6.25e-05	0.000184	CcSEcCtD
Sirolimus—Asthenia—Epirubicin—urinary bladder cancer	6.13e-05	0.00018	CcSEcCtD
Sirolimus—Pruritus—Epirubicin—urinary bladder cancer	6.05e-05	0.000178	CcSEcCtD
Sirolimus—Dizziness—Methotrexate—urinary bladder cancer	6.04e-05	0.000177	CcSEcCtD
Sirolimus—Diarrhoea—Epirubicin—urinary bladder cancer	5.85e-05	0.000172	CcSEcCtD
Sirolimus—Hypersensitivity—Doxorubicin—urinary bladder cancer	5.83e-05	0.000171	CcSEcCtD
Sirolimus—Vomiting—Methotrexate—urinary bladder cancer	5.81e-05	0.000171	CcSEcCtD
Sirolimus—Rash—Methotrexate—urinary bladder cancer	5.76e-05	0.000169	CcSEcCtD
Sirolimus—Dermatitis—Methotrexate—urinary bladder cancer	5.75e-05	0.000169	CcSEcCtD
Sirolimus—Headache—Methotrexate—urinary bladder cancer	5.72e-05	0.000168	CcSEcCtD
Sirolimus—Asthenia—Doxorubicin—urinary bladder cancer	5.67e-05	0.000167	CcSEcCtD
Sirolimus—Dizziness—Epirubicin—urinary bladder cancer	5.65e-05	0.000166	CcSEcCtD
Sirolimus—Pruritus—Doxorubicin—urinary bladder cancer	5.6e-05	0.000164	CcSEcCtD
Sirolimus—Vomiting—Epirubicin—urinary bladder cancer	5.43e-05	0.00016	CcSEcCtD
Sirolimus—Nausea—Methotrexate—urinary bladder cancer	5.43e-05	0.000159	CcSEcCtD
Sirolimus—Diarrhoea—Doxorubicin—urinary bladder cancer	5.41e-05	0.000159	CcSEcCtD
Sirolimus—Rash—Epirubicin—urinary bladder cancer	5.39e-05	0.000158	CcSEcCtD
Sirolimus—Dermatitis—Epirubicin—urinary bladder cancer	5.38e-05	0.000158	CcSEcCtD
Sirolimus—Headache—Epirubicin—urinary bladder cancer	5.35e-05	0.000157	CcSEcCtD
Sirolimus—Dizziness—Doxorubicin—urinary bladder cancer	5.23e-05	0.000154	CcSEcCtD
Sirolimus—Nausea—Epirubicin—urinary bladder cancer	5.08e-05	0.000149	CcSEcCtD
Sirolimus—Vomiting—Doxorubicin—urinary bladder cancer	5.03e-05	0.000148	CcSEcCtD
Sirolimus—Rash—Doxorubicin—urinary bladder cancer	4.99e-05	0.000146	CcSEcCtD
Sirolimus—Dermatitis—Doxorubicin—urinary bladder cancer	4.98e-05	0.000146	CcSEcCtD
Sirolimus—Headache—Doxorubicin—urinary bladder cancer	4.95e-05	0.000146	CcSEcCtD
Sirolimus—Nausea—Doxorubicin—urinary bladder cancer	4.7e-05	0.000138	CcSEcCtD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	2.93e-05	0.000135	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	2.92e-05	0.000135	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—KRAS—urinary bladder cancer	2.9e-05	0.000134	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NCOR1—urinary bladder cancer	2.89e-05	0.000134	CbGpPWpGaD
Sirolimus—MTOR—Disease—ERCC2—urinary bladder cancer	2.88e-05	0.000133	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—NQO1—urinary bladder cancer	2.88e-05	0.000133	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CXCL8—urinary bladder cancer	2.84e-05	0.000131	CbGpPWpGaD
Sirolimus—FGF2—Disease—CREBBP—urinary bladder cancer	2.84e-05	0.000131	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CDKN1A—urinary bladder cancer	2.81e-05	0.00013	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—PTEN—urinary bladder cancer	2.8e-05	0.000129	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.79e-05	0.000129	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—HRAS—urinary bladder cancer	2.79e-05	0.000129	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.79e-05	0.000129	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—KRAS—urinary bladder cancer	2.78e-05	0.000129	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL2—urinary bladder cancer	2.72e-05	0.000126	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	2.71e-05	0.000125	CbGpPWpGaD
Sirolimus—MTOR—Disease—MTHFR—urinary bladder cancer	2.71e-05	0.000125	CbGpPWpGaD
Sirolimus—MTOR—Disease—TERT—urinary bladder cancer	2.7e-05	0.000125	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CDKN1A—urinary bladder cancer	2.7e-05	0.000125	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—PTEN—urinary bladder cancer	2.69e-05	0.000124	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CDKN1A—urinary bladder cancer	2.69e-05	0.000124	CbGpPWpGaD
Sirolimus—MTOR—Immune System—FGFR3—urinary bladder cancer	2.68e-05	0.000124	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PTEN—urinary bladder cancer	2.68e-05	0.000124	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—EP300—urinary bladder cancer	2.67e-05	0.000123	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.65e-05	0.000123	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CCND1—urinary bladder cancer	2.65e-05	0.000122	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—NQO1—urinary bladder cancer	2.64e-05	0.000122	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CREBBP—urinary bladder cancer	2.63e-05	0.000121	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—SRC—urinary bladder cancer	2.6e-05	0.00012	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IGF1—urinary bladder cancer	2.59e-05	0.00012	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—HRAS—urinary bladder cancer	2.58e-05	0.000119	CbGpPWpGaD
Sirolimus—FGF2—Immune System—ERBB2—urinary bladder cancer	2.58e-05	0.000119	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MMP9—urinary bladder cancer	2.57e-05	0.000119	CbGpPWpGaD
Sirolimus—FGF2—Disease—RHOA—urinary bladder cancer	2.57e-05	0.000119	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CDKN1A—urinary bladder cancer	2.56e-05	0.000118	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—RRM2—urinary bladder cancer	2.56e-05	0.000118	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—PTEN—urinary bladder cancer	2.56e-05	0.000118	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—EP300—urinary bladder cancer	2.56e-05	0.000118	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TERT—urinary bladder cancer	2.55e-05	0.000118	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.52e-05	0.000116	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.52e-05	0.000116	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—SRC—urinary bladder cancer	2.5e-05	0.000115	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—SRC—urinary bladder cancer	2.48e-05	0.000115	CbGpPWpGaD
Sirolimus—MTOR—Disease—FGFR3—urinary bladder cancer	2.48e-05	0.000115	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TYMP—urinary bladder cancer	2.47e-05	0.000114	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—HRAS—urinary bladder cancer	2.46e-05	0.000114	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EP300—urinary bladder cancer	2.44e-05	0.000113	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.44e-05	0.000113	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.43e-05	0.000112	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GSTP1—urinary bladder cancer	2.4e-05	0.000111	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—S100B—urinary bladder cancer	2.39e-05	0.00011	CbGpPWpGaD
Sirolimus—FGF2—Disease—ERBB2—urinary bladder cancer	2.38e-05	0.00011	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—RHOA—urinary bladder cancer	2.38e-05	0.00011	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.37e-05	0.00011	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—SRC—urinary bladder cancer	2.37e-05	0.00011	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ENO2—urinary bladder cancer	2.37e-05	0.00011	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	2.37e-05	0.00011	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—HRAS—urinary bladder cancer	2.37e-05	0.000109	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—FGFR3—urinary bladder cancer	2.34e-05	0.000108	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL2—urinary bladder cancer	2.34e-05	0.000108	CbGpPWpGaD
Sirolimus—FGF2—Disease—PTGS2—urinary bladder cancer	2.33e-05	0.000108	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.32e-05	0.000107	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.3e-05	0.000106	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	2.3e-05	0.000106	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CREBBP—urinary bladder cancer	2.29e-05	0.000106	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—EGFR—urinary bladder cancer	2.28e-05	0.000105	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ESR1—urinary bladder cancer	2.27e-05	0.000105	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDH1—urinary bladder cancer	2.27e-05	0.000105	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.26e-05	0.000104	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.24e-05	0.000104	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—NAT2—urinary bladder cancer	2.24e-05	0.000103	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—TYMS—urinary bladder cancer	2.23e-05	0.000103	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MYC—urinary bladder cancer	2.23e-05	0.000103	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GSTM1—urinary bladder cancer	2.21e-05	0.000102	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—NCOR1—urinary bladder cancer	2.21e-05	0.000102	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	2.2e-05	0.000102	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CDKN1A—urinary bladder cancer	2.2e-05	0.000102	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ERBB2—urinary bladder cancer	2.2e-05	0.000102	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PTEN—urinary bladder cancer	2.2e-05	0.000102	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—EGFR—urinary bladder cancer	2.19e-05	0.000101	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—EGFR—urinary bladder cancer	2.18e-05	0.000101	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—KRAS—urinary bladder cancer	2.15e-05	9.94e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NCOR1—urinary bladder cancer	2.15e-05	9.92e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MYC—urinary bladder cancer	2.13e-05	9.82e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GPX1—urinary bladder cancer	2.11e-05	9.77e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CREBBP—urinary bladder cancer	2.11e-05	9.75e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—EP300—urinary bladder cancer	2.1e-05	9.69e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CXCL8—urinary bladder cancer	2.09e-05	9.64e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EGFR—urinary bladder cancer	2.08e-05	9.61e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ERCC2—urinary bladder cancer	2.08e-05	9.59e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	2.07e-05	9.57e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—KRAS—urinary bladder cancer	2.07e-05	9.55e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—KRAS—urinary bladder cancer	2.06e-05	9.51e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—TYMS—urinary bladder cancer	2.05e-05	9.47e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—SRC—urinary bladder cancer	2.04e-05	9.42e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—CDKN1A—urinary bladder cancer	2.04e-05	9.4e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—PTEN—urinary bladder cancer	2.03e-05	9.38e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	2.03e-05	9.36e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	2.03e-05	9.36e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL2—urinary bladder cancer	1.99e-05	9.21e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.99e-05	9.21e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CREBBP—urinary bladder cancer	1.99e-05	9.2e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IGF1—urinary bladder cancer	1.97e-05	9.08e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—KRAS—urinary bladder cancer	1.96e-05	9.07e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.96e-05	9.04e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—MTHFR—urinary bladder cancer	1.95e-05	9.01e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCND1—urinary bladder cancer	1.94e-05	8.98e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GPX1—urinary bladder cancer	1.94e-05	8.96e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—EP300—urinary bladder cancer	1.94e-05	8.95e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.93e-05	8.92e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ERBB2—urinary bladder cancer	1.91e-05	8.84e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—NQO1—urinary bladder cancer	1.91e-05	8.83e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—RHOA—urinary bladder cancer	1.91e-05	8.82e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.91e-05	8.81e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	1.9e-05	8.8e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TERT—urinary bladder cancer	1.89e-05	8.74e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MMP9—urinary bladder cancer	1.89e-05	8.72e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—SRC—urinary bladder cancer	1.88e-05	8.7e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.88e-05	8.69e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PTEN—urinary bladder cancer	1.88e-05	8.67e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—HRAS—urinary bladder cancer	1.83e-05	8.45e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—RHOA—urinary bladder cancer	1.8e-05	8.32e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	1.79e-05	8.27e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EP300—urinary bladder cancer	1.79e-05	8.27e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.79e-05	8.26e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.79e-05	8.26e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—EGFR—urinary bladder cancer	1.79e-05	8.26e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—ERBB2—urinary bladder cancer	1.77e-05	8.16e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HRAS—urinary bladder cancer	1.76e-05	8.11e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HRAS—urinary bladder cancer	1.75e-05	8.08e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—urinary bladder cancer	1.75e-05	8.07e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SRC—urinary bladder cancer	1.74e-05	8.04e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FGFR3—urinary bladder cancer	1.74e-05	8.02e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.73e-05	8.02e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL2—urinary bladder cancer	1.73e-05	8.01e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTGS2—urinary bladder cancer	1.73e-05	7.98e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KRAS—urinary bladder cancer	1.69e-05	7.8e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MYC—urinary bladder cancer	1.69e-05	7.8e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ESR1—urinary bladder cancer	1.69e-05	7.79e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HRAS—urinary bladder cancer	1.67e-05	7.71e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ERBB2—urinary bladder cancer	1.67e-05	7.7e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—EGFR—urinary bladder cancer	1.65e-05	7.63e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDKN1A—urinary bladder cancer	1.64e-05	7.56e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PTEN—urinary bladder cancer	1.63e-05	7.54e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.62e-05	7.5e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	1.59e-05	7.36e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PPARG—urinary bladder cancer	1.58e-05	7.31e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CXCL8—urinary bladder cancer	1.58e-05	7.31e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MYC—urinary bladder cancer	1.56e-05	7.2e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—KRAS—urinary bladder cancer	1.56e-05	7.2e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EP300—urinary bladder cancer	1.56e-05	7.19e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EGFR—urinary bladder cancer	1.53e-05	7.05e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.52e-05	7.04e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CREBBP—urinary bladder cancer	1.52e-05	7.02e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—SRC—urinary bladder cancer	1.51e-05	6.99e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL2—urinary bladder cancer	1.51e-05	6.98e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CDKN1A—urinary bladder cancer	1.51e-05	6.98e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTEN—urinary bladder cancer	1.51e-05	6.96e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—TYMS—urinary bladder cancer	1.48e-05	6.84e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CREBBP—urinary bladder cancer	1.48e-05	6.83e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCND1—urinary bladder cancer	1.47e-05	6.81e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	1.46e-05	6.77e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	1.46e-05	6.77e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IGF1—urinary bladder cancer	1.46e-05	6.74e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PPARG—urinary bladder cancer	1.45e-05	6.71e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.44e-05	6.66e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KRAS—urinary bladder cancer	1.44e-05	6.66e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—EP300—urinary bladder cancer	1.44e-05	6.64e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HRAS—urinary bladder cancer	1.44e-05	6.63e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MMP9—urinary bladder cancer	1.43e-05	6.61e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.43e-05	6.58e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PTEN—urinary bladder cancer	1.42e-05	6.57e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GPX1—urinary bladder cancer	1.4e-05	6.48e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—SRC—urinary bladder cancer	1.4e-05	6.46e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	1.39e-05	6.44e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.38e-05	6.37e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	1.38e-05	6.36e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EP300—urinary bladder cancer	1.36e-05	6.27e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RHOA—urinary bladder cancer	1.34e-05	6.18e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EGFR—urinary bladder cancer	1.33e-05	6.13e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—HRAS—urinary bladder cancer	1.33e-05	6.12e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SRC—urinary bladder cancer	1.32e-05	6.09e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	1.29e-05	5.98e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—urinary bladder cancer	1.28e-05	5.92e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KRAS—urinary bladder cancer	1.25e-05	5.79e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MYC—urinary bladder cancer	1.25e-05	5.79e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTGS2—urinary bladder cancer	1.24e-05	5.75e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ERBB2—urinary bladder cancer	1.24e-05	5.72e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—EGFR—urinary bladder cancer	1.22e-05	5.66e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HRAS—urinary bladder cancer	1.22e-05	5.66e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.2e-05	5.56e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.19e-05	5.5e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MYC—urinary bladder cancer	1.18e-05	5.46e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CXCL8—urinary bladder cancer	1.17e-05	5.42e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—KRAS—urinary bladder cancer	1.16e-05	5.35e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EGFR—urinary bladder cancer	1.16e-05	5.34e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	1.14e-05	5.28e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL2—urinary bladder cancer	1.12e-05	5.18e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.12e-05	5.16e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.11e-05	5.11e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.11e-05	5.11e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.1e-05	5.09e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.1e-05	5.09e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCND1—urinary bladder cancer	1.09e-05	5.05e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KRAS—urinary bladder cancer	1.09e-05	5.04e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTEN—urinary bladder cancer	1.09e-05	5.01e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.07e-05	4.94e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HRAS—urinary bladder cancer	1.07e-05	4.92e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MMP9—urinary bladder cancer	1.06e-05	4.9e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.06e-05	4.89e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CDKN1A—urinary bladder cancer	1.06e-05	4.89e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PTEN—urinary bladder cancer	1.06e-05	4.88e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PPARG—urinary bladder cancer	1.05e-05	4.85e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.04e-05	4.8e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—EP300—urinary bladder cancer	1.04e-05	4.78e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	1.01e-05	4.66e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EP300—urinary bladder cancer	1.01e-05	4.65e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTEN—urinary bladder cancer	9.96e-06	4.6e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—HRAS—urinary bladder cancer	9.84e-06	4.54e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SRC—urinary bladder cancer	9.79e-06	4.52e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—MTHFR—urinary bladder cancer	9.77e-06	4.51e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—urinary bladder cancer	9.71e-06	4.48e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—EP300—urinary bladder cancer	9.5e-06	4.39e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HRAS—urinary bladder cancer	9.28e-06	4.29e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NQO1—urinary bladder cancer	8.88e-06	4.1e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MYC—urinary bladder cancer	8.77e-06	4.05e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EGFR—urinary bladder cancer	8.58e-06	3.96e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	8.26e-06	3.81e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KRAS—urinary bladder cancer	8.1e-06	3.74e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PPARG—urinary bladder cancer	7.92e-06	3.66e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CREBBP—urinary bladder cancer	7.61e-06	3.51e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	7.41e-06	3.42e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—urinary bladder cancer	7.2e-06	3.33e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTEN—urinary bladder cancer	7.2e-06	3.33e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TYMS—urinary bladder cancer	6.89e-06	3.18e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HRAS—urinary bladder cancer	6.89e-06	3.18e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—EP300—urinary bladder cancer	6.87e-06	3.17e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	6.81e-06	3.15e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	6.81e-06	3.15e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GPX1—urinary bladder cancer	6.52e-06	3.01e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	6.4e-06	2.96e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTGS2—urinary bladder cancer	6.23e-06	2.88e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	6.02e-06	2.78e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTEN—urinary bladder cancer	5.43e-06	2.51e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—EP300—urinary bladder cancer	5.18e-06	2.39e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.88e-06	2.25e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.69e-06	2.17e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.84e-06	1.77e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.35e-06	1.55e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.19e-06	1.47e-05	CbGpPWpGaD
